News | EP Lab | April 26, 2021

Study Shows Risks of Anxiety and Depression After Cardiac Device Implantation

Patients receiving an implantable cardioverter defibrillator (ICD) should be regularly screened for anxiety and depression, according to research presented at European Heart Rhythm Association (EHRA) 2021 conference. ICD depression

April 26, 2021 — Patients receiving an implantable cardioverter defibrillator (ICD) should be regularly screened for anxiety and depression, according to research presented at European Heart Rhythm Association (EHRA) 2021 conference this week, an online scientific congress of the European Society of Cardiology (ESC).[1]

“Most patients adapt well to living with an ICD. For others it completely changes their life, with worries about shocks from the device, body image, and livelihood as some need to change their job,” said study author Professor Susanne Pedersen of Odense University Hospital, Denmark.

Previous studies have shown that anxious or depressed ICD patients have poorer quality of life and increased risks of arrhythmias and death.[2,3,4] This study examined how many patients develop anxiety or depression after ICD implantation, as screening tends to be a one-time event.

The study used data from DEFIB-WOMEN, a national, multicentre, prospective, observational study of patients with a first-time ICD.[5,6] Patients who received a first-time ICD were recruited consecutively between June 2010 to April 2013 at five hospitals in Denmark and followed up for 24 months.

The study included 1,040 patients who completed questionnaires on anxiety, depression, and physical quality of life at baseline, and 3, 6, 12, and 24 months. Information on demographic and clinical data was obtained from the Danish Pacemaker and ICD Register.

With respect to new onset anxiety, the cumulative incidence over the 24-month follow-up period was 14.5%. With respect to new onset depression, the cumulative incidence over the 24-month follow-up period was 11.3%.

Greater age was associated with a reduced risk of new onset anxiety, with a hazard ratio (HR) of 0.54, while being married, Type D personality, and lower self-reported physical functioning were associated with an increased risk, with HRs of 1.66, 2.50, and 1.48, respectively.

Regarding new onset depression, higher age and higher self-reported physical functioning were associated with reduced risk, with HRs of 0.57 and 0.46, respectively. Smoking, type D personality, and lower self-reported physical functioning were associated with an increased risk, with HRs of 2.13, 2.53, and 1.64, respectively.

“Our results suggest that more regular screening for depression and anxiety could identify patients who might benefit from additional support,” said Professor Pedersen. “Taken together, our findings indicate that younger patients, those with poor physical function, and those with type D personality are more likely to become anxious or depressed. People with type D personality tend to worry while not sharing negative emotions with others, which may compromise their mental health.”

Professor Pedersen noted that ICD implantation is often a day procedure. While some patients look forward to going home, others become anxious and feel it is too soon as they have had no time to adjust. She said: “One way to remedy this could be digital support, using an app or platform to provide information and reassurance, enabling patients to talk to a health professional if needed, and referring those with high anxiety or depression scores to a psychologist for an online treatment programme. We are piloting this approach, and in my experience, it is a minority of patients who need it, but for those who do, it can mean a world of difference.”

Funding: The DEFIB-WOMEN study is supported with a grant (09-10-R75-A2713-22565) from the Danish Heart Foundation.

References:

1. EHRA 2021 virtual meeting abstract title: New onset depression and anxiety in patients with an implantable cardioverter defibrillator during 24 months of follow-up.

2. Habibović M, Pedersen SS, van den Broek KC, et al. Anxiety and risk of ventricular arrhythmias or mortality in patients with an implantable cardioverter defibrillator. Psychosom Med. 2013;75:36-41.

3. Andersen CM, Theuns DAMJ, Johansen JB, et al. Anxiety, depression, ventricular arrhythmias and mortality in patients with an implantable cardioverter defibrillator: 7 years' follow-up of the MIDAS cohort. Gen Hosp Psychiatry. 2020;66:154–160.

4. Mastenbroek MH, Versteeg H, Jordaens L, et al. Ventricular tachyarrhythmias and mortality in patients with an implantable cardioverter defibrillator: impact of depression in the MIDAS cohort. Psychosom Med. 2014;76:58–65.

Related Content

News | Cardiovascular Clinical Studies

May 26, 2022 — For more than 20 years, scientists have known that people with hypertension, diabetes, high cholesterol ...

Home May 26, 2022
Home
News | Cardiovascular Clinical Studies

May 25, 2022 — Researchers from the group of Eva van Rooij used advanced sequencing technology to better understand the ...

Home May 25, 2022
Home
News | Cardiovascular Clinical Studies

May 23, 2022 — A specific protein in blood vessel cells plays a major role in the development of vascular and ...

Home May 23, 2022
Home
News | Cardiovascular Clinical Studies

May 20, 2022 — Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin ...

Home May 20, 2022
Home
News | Cardiovascular Clinical Studies

May 11, 2022 — Hypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a ...

Home May 11, 2022
Home
News | Cardiovascular Clinical Studies

May 5, 2022 — High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a ...

Home May 05, 2022
Home
News | Cardiovascular Clinical Studies

April 7, 2022 – Patients with tricuspid regurgitation, a common and debilitating form of valvular heart disease, who ...

Home April 07, 2022
Home
News | Cardiovascular Clinical Studies

April 7, 2022 – While there are effective therapies to reduce the risk of heart disease by lowering low-density ...

Home April 06, 2022
Home
News | Cardiovascular Clinical Studies

March 25, 2022 – Despite recent efforts to improve women’s leadership in cardiovascular clinical trial research over the ...

Home March 25, 2022
Home
News | Cardiovascular Clinical Studies

We are launching something new—a Clinical Case of the Month—and we want you to contribute! Do you have a clinical case ...

Home February 17, 2022
Home
Subscribe Now